AZD6234 for adults with obesity or overweight and no type 2 diabetes
Tests AZD6234 against placebo in adults with obesity or overweight.
Plain-language title generated from the registry record
Registry title: A Study to Evaluate Effect of AZD6234 in Adult Participants With Obesity or Overweight With Weight-related Comorbidity Without Type 2 Diabetes Mellitus
Key facts
- Where
- Bialystok, Cracow, Elblag, Gdynia, Katowice, Legnica, Lodz, Poznan, Radzionkow, Warsaw, and Wroclaw, PolandSee the 15 sites
- Phase
- Phase 3
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with obesity, or with overweight and at least one weight-related health problem, who do not have diabetes. AZD6234 is compared with placebo over 68 weeks.
- Age
- 18 years or older
- Sex
- All sexes and genders can join.
- Disease stage
- BMI 30 kg/m2 or higher, or BMI 27 kg/m2 or higher with at least one weight-related health problem such as high blood pressure, high blood fats, sleep apnoea, heart disease, heart failure, chronic kidney disease, fatty liver disease, knee osteoarthritis or stress urinary incontinence.
- Earlier treatment
- Must have had at least one unsuccessful attempt to lose weight in their lifetime. Must not have had a GLP-1 receptor agonist or GLP-1 containing medicine within 3 months before randomisation.
Main reasons for not taking part
- Obesity mainly caused by other hormone disorders
- Type 1 or Type 2 diabetes, HbA1c 6.5% (48 mmol/mol) or higher, or glucose-lowering medicine in the 3 months before screening
- Significant liver or bile duct disease, or ALT or AST 3.0 × ULN or higher, or TBL above 1.5 × ULN at screening
- Body weight change of more than 5% in the 3 months before randomisation
- GLP-1 medicine within 3 months before randomisation
Read by machine on 9 November 2026.
Where in Poland
- Kresmed Sp. z o. o.Bialystok, PolandTaking people
- Linden Sp. z o.o. sp.k.Cracow, PolandTaking people
- Unicardia Specjalistyczne Centrum Leczenia Chorob Serca I Naczyn & Unimedica Specjalistyczne Centrum Medyczne & Uniestetica Centrum Chirurgii Plastycznej Rekonstrukcyjnej I Medycyny Estetycznej Malopolskie Kliniki Specjalistyczne Sp. z o.o.Cracow, PolandTaking people
- Ambulatorium Sp. z o.o.Elblag, PolandTaking people
- Pratia S.A.Gdynia, PolandTaking people
- Pratia S.A.Katowice, PolandTaking people
- Salvia Lekston I Madej Sp. J.Katowice, PolandTaking people
- Beata Miklaszewicz & Dariusz Dabrowski Cardiamed Sp. j.Legnica, PolandTaking people
- Centrum Terapii Wspolczesnej J.M. Jasnorzewska S.K.A.Lodz, PolandTaking people
- Gabinet Lekarski Malgorzata Saryusz-WolskaLodz, PolandTaking people
- Uniwersyteckie Centrum Stomatologii i Medycyny Specjalistycznej Sp. z o.o.Poznan, PolandTaking people
- Tevita Clinical Sp. z o.o.Radzionkow, PolandTaking people
- Care Access Polska Sp. Z o.o.Warsaw, PolandTaking people
- Futuremeds Sp. z o.o.Warsaw, PolandTaking people
- Futuremeds Sp. z o.o.Wroclaw, PolandTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- AstraZeneca
- Trial code
- NCT07784725EU 2025-523379-41-00
- Record updated
- 30 October 2026
- Original description
The study will evaluate how well AZD6234 works and how safe it is in adults with excess weight or obesity. Efficacy of AZD6234 will be compared to placebo in percent body weight change from baseline at 68 weeks of treatmentRead full original descriptionShow less
A Phase III Randomised, Double-Blind, Placebo-Controlled Multicentre Trial to Evaluate the Efficacy and Safety of AZD6234 in Participants With Obesity or Overweight With at Least One Weight-Related Comorbidity Without Type 2 Diabetes Mellitus (SELENE 1)
The study will evaluate how well AZD6234 works and how safe it is in adults with excess weight or obesity. Efficacy of AZD6234 will be compared to placebo in percent body weight change from baseline at 68 weeks of treatment
Inclusion: Males \& females (inclusive of all gender identities) age ≥18 years; BMI ≥30 kg/m2 OR BMI ≥27 kg/m2 with at least one of the following weight related comorbidities (treated or untreated): hypertension, dyslipidaemia, obstructive sleep apnoea, cardiovascular disease, heart failure, chronic kidney disease, metabolic dysfunction-associated steatotic liver disease, osteoarthritis of the knee, or stress urinary incontinence; Stable body weight (≤5% body weight change) for at least 3 months prior to Randomisation; History of at least one self-reported unsuccessful attempt to lose body weight in their lifetime.
Exclusion: Has received treatment with a GLP-1 receptor agonist or GLP-1 containing medication for any indication within 3 months before Randomisation; Obesity primarily caused by other endocrine disorders; History of Type 1 or Type 2 Diabetes Mellitus, HbA1c ≥6.5% (48 mmol/mol), and/or treatment with glucose-lowering agent(s) within 3 months prior to Screening; Significant hepatobiliary disease and/or any of the following results at Screening:; ALT ≥ 3.0 × ULN; AST ≥ 3.0 × ULN; TBL > 1.5 × ULN (except for cases of known Gilbert's Syndrome).